Skip to main content
SpringerLink
Log in

Biochemical Evidence for Synergistic Combination Treatment with Methotrexate and 6-Mercaptopurine in Acute Lymphoblastic Leukemia

  • Conference paper
Acute Leukemias II

Part of the book series: Haematology and Blood Transfusion / Hämatologie und Bluttransfusion ((HAEMATOLOGY,volume 33))

Abstract

Methotrexate (MTX) and 6-mercaptopurine (6 MP) are common antimetabolites in the treatment of acute lymphoblastic leukemia (ALL) since their introduction in 1947 and 1952 [1, 2]. Originally, these agents were administered separately. However, after empirical evidence for a potentiating efficacy of the combination of both in mice leukemia [3], MTX and 6 MP have also been used in combination in childhood ALL. The enhanced efficacy of combination treatment in children was demonstrated in a study of the Acute Leukemia Group B in 1961 [4].

This work was supported by the Dutch Queen Wilhelmina Cancer Foundation (KWF), grant NUKC 82-3.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Seeger DR, Smith JM Jr, Hultquist ME (1947) Antagonist for pteroylglutamic acid. J Am Chem Soc 69:2567

    Article  PubMed  CAS  Google Scholar 

  2. Elion G, Burgi E, Hitchings GH (1952) Studies on condensed pyrimidine systems. IX. The synthesis of some 6-substituted purines. J Am Chem Soc 74:411–414

    Article  CAS  Google Scholar 

  3. Law LW, Taormina V, Boyle PJ (1954) Response of acute lymphocytic leukemias to the purine antagonist 6-mercaptopurine. Ann N Y Acad Sci 60:244–250

    Article  PubMed  CAS  Google Scholar 

  4. Frei E III, Freireich EJ, Gehan E et al. (1961) Studies of sequential and combination antimetabolite therapy in acute leukemia:6-mercaptopurine and methotrexate. Blood 18:431–454

    Google Scholar 

  5. Riehm H, Feickert H-J, Lampert F (1986) Acute lymphoblastic leukemia. In:Voute PA, Barnett A, Bloom HJG et al. (eds) Cancer in children. Clinical management. Springer, Berlin Heidelberg New York, pp 101–118

    Google Scholar 

  6. Zimm S, Collins JM, Riccardi R et al. (1983) Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered. N Engl J Med 308:1005–1009

    Article  PubMed  CAS  Google Scholar 

  7. Lennard L, Lilleyman JS (1987) Are children with lymphoblastic leukaemia given enough 6-mercaptopurine? Lancet ii:785–787

    Article  Google Scholar 

  8. Evans WE, Crom WR, Stewart CF et al. (1984) Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia. Lancet i:359–362

    Article  Google Scholar 

  9. Pinkerton CR, Welshman SG, Kelly JG et al. (1982) Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 10:36–39

    Article  PubMed  CAS  Google Scholar 

  10. Zimm S, Ettinger LC, Holcenberg et al. (1985) Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. Cancer Res 45:1869–1873

    PubMed  CAS  Google Scholar 

  11. Schouten TJ, De Abreu RA, Schretlen EDAM et al. (1986) 6-Mercaptopurine:high-dose 24-h infusions in goats. J Cancer Res Clin Oncol 112:61–66

    Article  PubMed  CAS  Google Scholar 

  12. Bökkerink JPM, Bakker MAH, Hulscher TW etal. (1986) Sequence-, time- and dose-dependent synergism of methotrexate and 6-mercaptupurine in malignant human T-lymphoblasts. Biochem Pharmacol 35:3549–3555

    Article  PubMed  Google Scholar 

  13. Bökkerink JPM, De Abreu RA, Bakker MAH etal. (1986) Dose-related effects of methotrexate on purine and pyrimidine nucleotides and on cell-kinetic parameters in MOLT-4 malignant human lymphoblasts. Biochem Pharmacol 35:3557–3564

    Article  PubMed  Google Scholar 

  14. Bökkerink JPM, Bakker MAH, Hulscher TW et al. (1988) Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages. Biochem Pharmacol 37:2321–2327

    Article  PubMed  Google Scholar 

  15. Bökkerink JPM, De Abreu RA, Bakker MAH et al. (1988) Effects of methotrexate on purine and pyrimidine metabolism and cell- kinetic parameters in human malignant lymphoblasts of different lineages. Biochem Pharmacol 37:2329–2338

    Article  PubMed  Google Scholar 

  16. Bökkerink JPM, Damen FJM, Hulscher TW et al. 6-Mercaptopurine:cytotoxicity and bio-chemical pharmacology in human malignant lymphoblasts of different lineages. Biochem Pharmacol (to be published)

    Google Scholar 

  17. Webb JL (1963) Antagonism, summation, and synergism. In:Webb JL (ed) Enzyme and metabolic inhibitors, vol 1. Academic Press, New York, pp 507–510

    Google Scholar 

  18. Schouten TJ, De Abreu RA, De Bruijn CHMM et al. (1984) 6-Mercaptopurine pharmacokinetics in animals and preliminary results in children. Adv Exp Med Biol 165B:367–370

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Pediatric Oncology S.E. Netherlands, Department of Pediatric, University Hospital of Nijmegen, 6500 HB, Nijmegen, The Netherlands

    J. P. M. Bökkerink, F. J. M. Damen, M. W. Hulscher, M. A. H. Bakker & R. A. De Abreu

Authors
  1. J. P. M. Bökkerink
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. J. M. Damen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. W. Hulscher
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. A. H. Bakker
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. A. De Abreu
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Departments of Internal Medicine and Pediatrics, University of Münster, Albert-Schweitzer-Straße 33, D-4400, Münster, Federal Republic of Germany

    T. Büchner , G. Schellong , W. Hiddemann  & J. Ritter , ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Bökkerink, J.P.M., Damen, F.J.M., Hulscher, M.W., Bakker, M.A.H., De Abreu, R.A. (1990). Biochemical Evidence for Synergistic Combination Treatment with Methotrexate and 6-Mercaptopurine in Acute Lymphoblastic Leukemia. In: Büchner, T., Schellong, G., Hiddemann, W., Ritter, J. (eds) Acute Leukemias II. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 33. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74643-7_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-74643-7_20

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-50984-4

  • Online ISBN: 978-3-642-74643-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation